Member Info for 42trader

Problem I see is the forward pe is based on next years growth and that may or may not happen. Investors and institutions want to see the actual figures before buying in. So imo the sp will be muted until that happens. Also I’m a little worried markets will crash before then. I’m half expecting a crash in this later half of the year and with what is currently going on around the world I wouldn’t be surprised if it’s starting now. I do think vlg will come good eventually but I think it’s looking like a 2 year plus play.

I think 50p will likely be hit. Negativity about the company will take time to get over and even though the bad news is out now, it will still take a dent when the results come out.
Also 50p is the price vlg was at when it got the news of the number order of hand sanitizer last year so a return to that level it quite likely. There’s a gap in the charts from 50p when it jumped up on the sanitizer order RNS so a good chance it will be filled. The good news would be that 50p is quite a strong support level so hopefully it won’t drop past that. It may take some time now to recover as I reckon the market will want to see the proof in the pudding with the new acquisitions and that will mean waiting until at least the next set of results.

Yep it’s a profits warning for sure, but was it unexpected?
We knew the Chinese order was struggling to sell and the hand sanitiser uplift last year was a one off.
As for being sugar coated by 8% growth without the Chinese order, it comes more in line with 2019. The business continues to grow. Add in the recent two acquisitions and the company will continue to grow yoy. Vlg also have other acquisitions they hope to make in the future.
I certainly wish I had sold first thing at 13p down but didn’t expect the drop to go further. I have bought more now at below 80p as I always intended to hold this for 5 years plus with the intention of collecting a sizeable holding for when a dividend is paid hopefully in late 2022 to 2023.

Yep good write up showing latest drill as the second best exploration results across all key commodities for this year.
Liberum have given a target price of 35p, almost a 3 bagger from the current price.

Some analysts still calling gold to rise above 2000 later in year into 2022. This is the time frame many have been calling all year so nothing really changed.

https://youtu.be/xXQU1eVt0yg

I agree with you about talk of other companies.
The current price of BOO is at support and bottom of a daily trend so there is a good chance it will bounce from here. If not, there is support at approx. £2 and that is also the bottom of a weekly trend line. Tbh I wouldn't mind it dropping to that price as it would be nice to add at that level.

A good trading update. Unfortunately the negative comment has caused the share price to fall a little. I have seen this plenty of times and it does not worry me as I believe the next results will show the company hitting the forecasts or beating them which in turn will take the sp higher later. It may fall a bit bellow 50p which imo will be a buying opportunity as that will be a drop of a third from recent high. You have to remember that no share goes straight up and as a recovery play you have to take a longer term view of a few years.

Gla

On a technical side, yesterdays share price dropped to a strong support level. It was also at a price where many investors would place a stop lose, so to take it down and trigger those stops is a common trick to do. RSI and STOCH are also in oversold territory.
By the sound of some people's comments on here, Boohoo is on the verge of going bust, yet the reality is, the company keeps breaking the forecasts. It very much reminds me of the drop in the share price of Apple back in April 2013. Apple was being slated big time and scare mongering made out it had seen it's day and it was all down hill from there on.
No share is perfect, they all have their ups and downs, but imo, when a company is continuously breaking their forecasts, you buy the dips.

gla

Happy to add some more here this morning. Long may the drop continue.
I love the fact that there are posters continually de-ramping this share. Some should learn to get a life.
Boohoo has always been a volatile share. Investors need to look through all the noise and if they believe in a company then holding through the ups and downs is not a problem in the long term.

Must be talking of falling lumber prices.

Nothing to see here. Wake me up when the sp is 45p+.

This will allow vlg funds of up to £42m for future acquisitions after they have paid of the Italian loan of €6m. Hopefully we will see the talked about Vulcan and other acquisitions soon.

Looks like your covered. I think too we may see one more spike up in equities. Just a matter of waiting now.

Well the pog has consolidated nicely after breaking out of the downward trend channel. Ready to see a continued rise to 2000 and then beyond. Just need a catalyst to spur it on. Could today be the day?

I wonder if we will see more bod buys rns as there has been some big trades going through.

Should see a steady rise over next few years. Atm it’s the IC tip that’s raising the sp. Should see a rise for a few days as other investors read the report with their mag out on Friday.
Then we are due a company update in the next month as well as possible acquisitions of Vulcan and maybe 2 others.
Then it will be interims. Each one should provide a further increase in the share price.
Well if ST thinks he clever at tipping at 45p I beat him buying at 34p. It’s a long term hold for me as all I see it doing is rise for the next 5 years.

Plenty to read today with 2 broker reports out. You can view the Cenkos report for free from their web page or register with ResearchTree.
Quite a hefty price tag for BBI Healthcare but looks a good acquisition. A growing company that has invested in the last year. 25% profit margins, which is more than double that of VLG. If VLG do indeed grow the EBITDA to a high single digit figure this year alone then the price looks good. Add in possible synergies and cross selling and BBI could be doing £10m EBITDA in 2022, which is triple that of VLG for last year.
If VLG do buy Vulcan as well, then VLG could be close to £15m come the end of 2022. Going on a conservative estimate of 15x multiple, then the company should be valued at double the current price.
As they say though, the proof is in the pudding, so we will have to wait and see. But this is starting to look interesting again and I see no reason to not continue to hold.
I would expect a dividend to start some time in 2023, which would attract more investors.

The point is that although housebroker Cenkos Securities is holding fire on upgrading its estimates for now, then we are guaranteed some hefty uplifts later this summer. Analysts currently expect Venture’s cash profit (pre-BBI acquisition) to increase 14 per cent to £7m on 10 per cent higher revenue of £33.3m. However, a six-month contribution in 2021 from BBI would increase Venture’s cash profit to £9m, implying 50 per cent year-on-year growth. On an annualised basis, group cash profit run rate will be closer to £11m, or 83 per cent higher than in 2020.

This implies Venture is being valued on a multiple of 10 times annualised cash profit to enterprise valuation, a modest rating for a company that is set to generate further revenue and cost benefits from BBI and has a cracking track record of integrating acquisitions.

The key reason why the shares have doubled since I initiated coverage, at 45p, in my May 2019 Alpha Report is management’s ability to outperform. The BBI acquisition and imminent news of further bolt-on deals are set to support further earnings upgrades, and that’s simply not being priced in. I maintain my 130p target price (‘Bagging value stock hatrick’, 23 November 2020). Buy.

Aim-traded Venture Life (VLG:92p), a developer, manufacturer and distributor of products for the self-care market, has announced the £36m acquisition of BBI Healthcare, a highly profitable global market leading women's health and diabetes/energy management company.

BBI’s key brands are Balance Activ, the leading UK brand for the treatment of bacterial vaginosis; Glucogel, the number one glucose gel prescribed in the UK for hypoglycemia; and Lift, a range of glucose gels, shots and chewable tablets. BBI owns all the IP associated with the brands which are sold or partnered across 27 countries. In addition, BBI has developed a new women’s health product and signed a distribution agreement with an [undisclosed] international partner for the new product to be launched under their own well-known brand in Europe, China and USA.

This is the first acquisition since Venture raised £34m placing and £2m open offer at 90p a share last November to fund its acquisition strategy. BBI reported adjusted cash profit of £2.6m on £10.2m revenue in 2020, and profits will be materially higher this year after taking account of product initiatives and cost synergies. In fact, the £36m acquisition has been priced on a “high single-digit cash profit multiple for 2021”, implying cash profit will grow by at least 50 per cent.

Moreover, there are multiple strategic benefits that will boost BBI’s profits in 2022 including cross-selling opportunities between Venture’s existing customer base, marketing BBI’s products through its enlarged distribution network, and utilising BBI’s manufacturing facilities in Sweden. They are currently running at 20 per cent capacity, thus offering a material opportunity to generate additional revenue by ramping up production.

Although the acquisition leaves Venture in a slightly positive net cash position, the group is putting in place a revolving credit facility to enable further acquisitions. Management expect to update the market soon on other deals in the pipeline including Project Vulcan, a company focused on oncology support therapies to treat the dermatological and oral side-effects of cancer treatments. Venture’s directors see an opportunity to increase the distribution of the brands' products into more territories using its own network of local partners, along with new partners. In 2019, Vulcan generated £3.5m in net sales and an estimated cash profit excess of £1.2m. The £5.5m consideration equates to 4.5 times cash profit.

I'm wondering if the recent rise was because of this news today.